483
BioChem Sioux City Inc.BioChem Sioux City Inc. – FDA 483, Aug 6, 2021
Record Details
Aspen API, Inc. in Sioux City, Iowa, was inspected regarding its crude heparin manufacturing, revealing significant issues with contamination control and product quality. The firm failed to adequately protect Crude Heparin Sodium from contamination and allowed untrained employees to overrule critical product release decisions. Additionally, the inspection found deficiencies in testing procedures and the accuracy of Certificates of Analysis.
View Company Profile
ID · 8cacec91-83aa-4431-af3e-1594777bb0cd
Other documents for BioChem Sioux City Inc.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.